Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 5, 2005, Pages 1057-1064

  Brousseau, Margaret E ^a   Diffenderfer, Margaret R ^a   Millar, John S ^b   Nartsupha, Chorthip ^a   Asztalos, Bela F ^a   Welty, Francine K ^c   Wolfe, Megan L ^b   Rudling, Mats ^d   Björkhem, Ingemar ^d   Angelin, Bo ^d   Mancuso, James P ^e   Digenio, Andres G ^e   Rader, Daniel J ^b   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e PFIZER INC   (United States)

Author keywords

Apolipoprotein A I; Bile acids; CETP inhibition; Cholesteryl ester transfer protein; High density lipoproteins; Kinetics

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE; PLACEBO; STEROL; TORCETRAPIB;

ADULT; AGED; ARTICLE; BILE ACID SYNTHESIS; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXCRETION; FECES ANALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STEROL METABOLISM;

EID: 20944437770     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000161928.16334.dd     Document Type: Article

References (47)

1. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
2. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
3. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
4. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc. 1988;260:641-651.
5. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J Am Med Assoc. 2001;285:1585-1591.
6. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 2002;164:361-369.
7. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23: 160-167.
8. Hesler CB, Swenson TL, Tall AR. Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 1987;262: 2275-2282.
9. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34: 1255-1274.
10. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R, Tall AR. 1989. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989;342:448-451.
11. Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H, Sakai Y, Sakai T, Ueda K, Takeda R. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis. 1985;58:175-186.
12. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
13. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H, Nagano M, Brewer HB Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 1993;92:1650-1658.
14. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc. 2003;290:2292-2300.
15. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497.
16. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with low HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
17. Lichtenstein AH, Hachey DL, Millar JS, Jenner JL, Booth L, Ordovas JM, Schaefer EJ. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine. J Lipid Res. 1992;33:907-914.
18. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
19. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987; 166:1-8.
20. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apoA-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291-300.
21. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine: effect of fasting and feeding. J Clin Invest. 1990;85: 804-811.
22. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: technical problems associated with leucine contamination in stable isotope studies. J Lipid Res. 1997;38:1535-1543.
23. Cobelli C, Toffolo G, Bier DM, Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol. 1987;253:E551-E564.
24. Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon-Fava S, Asztalos BF, Dolnikowski GG, Brousseau ME, Marsh JB. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism. 2004; 53:1255-1261.
25. Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (apo) B-48 and apoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol. 1999;19:2966-2974.
26. Lund E, Sisfontes L, Reihner E, Bjorkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest. 1989;49:165-171.
27. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, Einarsson K, Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990;323:224-228.
28. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res. 2003;44:859-865.
29. Miettinen TA, Ahrens EH Jr, Grundy SM. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res. 1965;6:411-424.
30. Grundy SM, Ahrens EH Jr, Miettinen TA. 1965. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal bile acids. J Lipid Res. 1965;6:397-410.
31. Miettinen TA. Gas-liquid chromatographic determination of fecal neutral steroids using a capillary column. Clin Chim Acta. 1982;124:245-248.
32. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591-611.
33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
34. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren RT, Aamodt RL, Brewer HB Jr. Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982;23:850-862.
35. Brinton EA, Eisenberg S, Breslow JL. Elevated high-density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 1989;84:262-269.
36. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size: effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb. 1994;14:707-720.
37. Melchior GW, Castle CK, Vidmar TJ, Polites HG, Marotti KR. ApoA-I metabolism in cynomolgus monkeys: male-female differences. Biochim Biophys Acta. 1990;1043:97-105.
38. Horowitz BS, Goldberg IJ, Merab J, Vanni T, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1991;91:1743-1752.
39. Liang H-Q, Rye K-A, Barter PJ. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res. 1994;35:1187-1199.
40. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670-2676.
41. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Change in alpha-1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847-852.
42. Asztalos BF, Lefevre M, Foster TA, Tulley R, Windhauser M, Wong L, Roheim PS. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. Arterioscler Thromb Vasc Biol. 1997; 17:1885-1893.
43. Asztalos BF, Horvath KV, Kojinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res. 2004;45: 448-455.
44. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer and output in vivo in humans. J Lipid Res. 2004;45: 1594-1607.
45. Kee P, Rye K-A, Morehouse L, Barrett PHR, Barter PJ. The effects of cholesteryl ester transfer protein (CETP) inhibition on the metabolism of cholesteryl esters in high density lipoproteins: insights into reverse cholesterol transport. 52nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, 8-11 August 2004, Brisbane, Queensland, Australia.
46. Morehouse LA, Sugarman ED, Bourassa P-A, Milici AJ. HDL elevation by the CETP-inhibitor torcetrapib prevents aortic atherosclerosis in rabbits. The Am Heart Association Scientific Sessions 2004, 7-10 November 2004, New Orleans, La, United States (Abstract 1168).
47. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation. 1999;100: 594-598.